TAXES ON INCOME (Tables)
|
12 Months Ended |
Jul. 31, 2026 |
|---|
| Income Tax Disclosure [Abstract] |
|
| SCHEDULE OF LOSS BEFORE TAXES ON INCOME |
SCHEDULE
OF LOSS BEFORE TAXES ON INCOME
| | |
2026 | | |
2025 | |
| | |
Year ended July 31, | |
| | |
2026 | | |
2025 | |
| Domestic | |
$ | (29,759,513 | ) | |
$ | (23,999,920 | ) |
| Foreign | |
| (5,565,779 | ) | |
| (2,556,220 | ) |
|
| SCHEDULE OF EFFECTIVE INCOME TAX |
SCHEDULE
OF EFFECTIVE INCOME TAX
| | |
2026 | | |
2025 | |
| | |
Year ended July 31, | |
| | |
2026 | | |
2025 | |
| Expected income tax (recovery) expense | |
| (9,537,829 | ) | |
| (7,170,160 | ) |
| Tax rate changes and effect of taxes of subsidiaries at foreign rates | |
| 1,785,571 | | |
| 1,448,710 | |
| Share-based compensation and other non-deductible expenses | |
| 531,294 | | |
| 240,070 | |
| Share issuance costs booked directly to equity | |
| (573,777 | ) | |
| (375,750 | ) |
| Adjustments in respect of prior periods | |
| 81,843 | | |
| 868,490 | |
| R&D credits | |
| (2,227,411 | ) | |
| (1,284,010 | ) |
| Valuation allowance | |
| 9,940,309 | | |
| 6,272,650 | |
| Income tax (recovery) | |
$ | - | | |
$ | - | |
|
| SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE AND THE EFFECTIVE INCOME TAX RATE |
SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE AND THE EFFECTIVE INCOME TAX RATE
| | |
| | | |
| | |
| | |
July 31, 2026 | |
| Reconciling item | |
Amount | | |
Percent | |
| Expected Income Tax (Recovery) Expense - Federal | |
$ | (5,298,794 | ) | |
| 15.00 | % |
| Canadian Provincial Tax Net of Federal Income Tax Effect | |
| (4,239,035 | ) | |
| 12.00 | % |
| Foreign tax effects | |
| 1,785,571 | | |
| (5.05 | )% |
| Tax Credits | |
| | | |
| | |
| Research and development credit | |
| (2,227,411 | ) | |
| 6.31 | % |
| Changes in valuation allowances | |
| 9,940,309 | | |
| (28.14 | )% |
| Nontaxable or Nondeductible Items | |
| | | |
| | |
| Share-based compensation and other nondeductible expenses | |
| 531,294 | | |
| (1.50 | )% |
| Other Adjustments | |
| | | |
| | |
| Share issuance costs recorded directly in equity | |
| (573,777 | ) | |
| 1.62 | % |
| Adjustments in respect of prior periods | |
| 81,843 | | |
| (0.24 | )% |
| Changes in unrecognized tax benefits | |
| - | | |
| 0.00 | % |
| Income tax recovery and effective income tax rate | |
$ | - | | |
| 0.00 | % |
|
| SCHEDULE OF DEFERRED TAX ASSETS NET |
SCHEDULE
OF DEFERRED TAX ASSETS NET
| | |
2026 | | |
2025 | |
| | |
July 31, | |
| | |
2026 | | |
2025 | |
| Deferred Tax Assets: | |
| | | |
| | |
| Property and equipment | |
$ | 731 | | |
$ | 730 | |
| Marketable securities | |
| 11,758 | | |
| 11,760 | |
| Intellectual property | |
| - | | |
| 260,860 | |
| Warrant liability | |
| - | | |
| - | |
| Share issuance costs | |
| 688,831 | | |
| 310,230 | |
| Investment in BC Therapeutics | |
| 67,766 | | |
| 44,650 | |
| Operating tax losses carried forward | |
| 5,674,627 | | |
| 5,067,840 | |
| Operating tax losses carried forward - USA | |
| 14,921,914 | | |
| 8,494,300 | |
| Research and development | |
| 14,016,183 | | |
| 14,240,640 | |
| Total deferred tax assets | |
| 35,381,810 | | |
| 28,431,010 | |
| Valuation allowance | |
| (35,075,129 | ) | |
| (24,329,720 | ) |
| Net deferred tax assets | |
$ | 306,681 | | |
$ | 4,101,290 | |
| Deferred Tax Liabilities: | |
| | | |
| | |
| Warrant liability | |
$ | (43,272 | ) | |
$ | (4,053,520 | ) |
| Intellectual property | |
| (206,654 | ) | |
| - | |
| Property, plant, and equipment | |
| (56,755 | ) | |
| (47,770 | ) |
| Total net deferred tax liabilities | |
| (306,681 | ) | |
| (4,101,290 | ) |
| Net deferred tax assets (liabilities) | |
$ | - | | |
$ | - | |
|